However, there are research studies suggesting that the JAK inhibitor baricitinib, with IFN-blocking activity might ameliorate COVID-19 symptoms(24)which even took a step further, suggesting combining antiviral and anti-inflammatory treatments, although considering concerns over virus remaining and reactivation later on (25). The gene discussed is IFNA1; the disease is COVID-19.